Lung cancer is the leading cause of cancer-related mortality in the United States. Despite great advances in the understanding of lung cancer biology, only 15% of patients are alive five years after diagnosis.

Novel agents hold great promise for lung cancer patients. A key development in cancer research over the past year is understanding how to rationally target the right treatments for the right patient in order to improve outcomes for all. The Center for Thoracic Cancers has played a major role in understanding the biology of the epidermal growth factor receptor (EGFR).

Visit the new cancer research website regarding ongoing clinical research in cancer of the lungs.